Alison Campbell Brewer, Ph.D.

Alison Campbell Brewer
Eli Lilly

Process Development and Scale-Up of a PI3Kα- Selective Inhibitor

This seminar will describe the development of an improved process for preparing hundreds of kilograms of a PI3Kα- selective inhibitor to support clinical trials. The evolution of the synthetic route and key process improvements made to position the asset for commercialization, including the elimination of problematic solvents and reagents, a 40-fold reduction in ruthenium loading for a key asymmetric reduction, and suppression of epimerization will be covered.

Alison Campbell Brewer

Alison Brewer received a B.S. in biochemistry from Lafayette College in 2004 and a PhD in inorganic chemistry in 2009 from the University of North Carolina under the supervision or Professor Mike Gagné. She spent two years as an NIH postdoctoral fellow at the University of Wisconsin with Professor Shannon Stahl. Alison joined the process chemistry group at Lilly in 2011 where she supported the development of a number of portfolio assets and was instrumental in establishing a high-throughput chemistry screening platform in process development. Alison currently serves as the scientific team lead for the Small Molecule Commercialization team, supporting development strategies for late-phase small molecule assets. late-phase small molecule assets.

Hosted by Professor Jessica Lamb
Sponsored by Gassman Funds